Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...
Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...
Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...
Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that autoimmune diseases affect 400 to 600 million people worldwide, with the burden ...
CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...
CAR T therapy improves survival in B-cell malignancies but presents toxicities like CRS, ICANS, ICAHT, and IEC-HS, requiring careful management. ICAHT is classified into early and late phases, with ...
DuoCAR20.19.22-D95 targets CD19, CD20, and CD22, addressing antigen escape in B-cell malignancies like B-ALL and B-NHL. Early-stage trials show no safety concerns for DuoCAR20.19.22-D95, with ongoing ...
CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...
Aera Therapeutics Presents Preclinical Data and Announces Nomination of First Development Candidate, AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases Preclinical data ...
The CD20 inhibitor Ocrevus (ocrelizumab) rapidly depletes immune B-cells in people with multiple sclerosis (MS), as expected, but ongoing treatment also leads to changes in immune T-cells, a new study ...
This manuscript provides valuable insights into the heterogeneity of hematopoietic stem cells and age-associated myeloid-biased hematopoiesis. While several aspects of the study are intriguing and ...
A person with multiple sclerosis (MS) has for the first time been treated with an “off-the-shelf” CAR T-cell therapy called azercabtagene zapreleucel (azer-cel), a donor-derived approach that’s never ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback